Logic Bio Therapeutics, Inc. LOGC
We take great care to ensure that the data presented and summarized in this overview for LogicBio Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LOGC
Top Purchases
Top Sells
About LOGC
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Insider Transactions at LOGC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Nov 16
2022
|
Daniel Gruskin Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,331
-100.0%
|
-
|
|
Nov 16
2022
|
Leon Chen Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,333
-100.0%
|
-
|
|
Nov 16
2022
|
Richard A Moscicki Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,916
-100.0%
|
-
|
|
Nov 16
2022
|
Frederic Chereau President, CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
253,811
-100.0%
|
-
|
|
Nov 16
2022
|
Michael S Wyzga Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,141
-100.0%
|
-
|
|
Nov 16
2022
|
Mark J Enyedy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,921
-100.0%
|
-
|
|
Nov 16
2022
|
Mark A Kay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
784,557
-100.0%
|
-
|
|
Jan 12
2022
|
Cecilia Jones Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,175
-36.62%
|
$4,350
$2.01 P/Share
|
|
Jan 11
2022
|
Cecilia Jones Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,939
+50.0%
|
-
|
|
Aug 09
2021
|
Daniel Gruskin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,467
-30.58%
|
$5,868
$4.35 P/Share
|
|
Aug 06
2021
|
Daniel Gruskin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,798
+50.0%
|
-
|
|
Apr 16
2021
|
Frederic Chereau President, CEO |
SELL
Open market or private sale
|
Direct |
7,542
-2.89%
|
$37,710
$5.73 P/Share
|
|
Apr 16
2021
|
Kyle Chiang Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,977
-11.29%
|
$14,885
$5.73 P/Share
|
|
Apr 15
2021
|
Frederic Chereau President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,414
+8.22%
|
-
|
|
Apr 15
2021
|
Kyle Chiang Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,360
+26.2%
|
-
|
|
Jan 01
2021
|
Richard A Moscicki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,916
+50.0%
|
-
|
|
Jan 01
2021
|
Michael S Wyzga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,141
+50.0%
|
-
|
|
Jan 01
2021
|
Mark J Enyedy Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,921
+50.0%
|
-
|
|
Jan 01
2021
|
Leon Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,298
+50.0%
|
-
|
|
Jan 01
2021
|
Mark A Kay Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,199
+50.0%
|
-
|